SEC Filing | MEI Pharma

View:

Download DOC

Download PDF

Download XLS

FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2006

Marshall Edwards, Inc.

(Exact name of registrant as specified in its charter)


DELAWARE	000-50484	51-0407811
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

140 Wicks Road, North Ryde, NSW, 2113 Australia
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (011) 61 2 8877-6196

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS


	Item 1.01. Entry into a Material Definitive Agreement.
	Item 9.01. Financial Statements and Exhibits.
Signature
EX-10.1: AMENDMENT DEED
EX-99.1: PRESS RELEASE

Item 1.01. Entry into a Material Definitive Agreement.

On June 7, 2006, Marshall Edwards Pty Limited (“MEPL”), a wholly owned subsidiary of Marshall Edwards, Inc. (the “Company”), and Novogen Research Pty Limited (“Novogen Research”), a wholly owned subsidiary of Novogen Limited, entered into an amendment deed (“Amendment”) to the Amended and Restated License Agreement, dated September 24, 2003, between the Company and Novogen Research.

Pursuant to the original terms of the Amended and Restated License Agreement, MEPL was required to pay an US $8,000,000 license milestone fee to Novogen Research in December 2006 for its use of the compound phenoxodiol. The Amendment extends the date that the US $8,000,000 license milestone fee is payable until the earlier of MEPL’s receipt of the U.S. Food and Drug Administration’s approval to market phenoxodiol in the United States or a foreign governmental agency’s approval to market phenoxodiol abroad.

Under the Amended and Restated License Agreement, Novogen Research granted MEPL an exclusive world-wide, non-transferable license, under the Novogen patent rights, to conduct clinical trials and commercialize and distribute all forms of administering phenoxodiol except topical applications. The Amended and Restated License Agreement covers uses of phenoxodiol in the field of prevention, treatment and cure of cancer in humans. The Amendment does not change the term of the Amended and Restated License Agreement which remains in effect until terminated by either Novogen Research or MEPL.

The terms of the Amendment were established through arms-length negotiations between the independent members of the board of directors of Novogen Limited and the independent members of the Company’s board of directors. The Amendment was unanimously approved by the board of directors of each of MEPL and the Company. A majority of the members of the Company’s board of directors are independent in accordance with Nasdaq listing requirements.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment filed as Exhibit 10.1 hereto, and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.


Exhibit No.		Description

10.1		Amendment Deed, dated June 7, 2006, by and between Novogen Research Party Limited and Marshall Edwards Pty Limited.

99.1		Press Release issued by Marshall Edwards, Inc., dated as of June 7, 2006.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		MARSHALL EDWARDS, INC.

		By:		/s/ David R. Seaton

				David R. Seaton Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer)

Dated: June 9, 2006

Index to Exhibits


Exhibit No.		Description

10.1		Amendment Deed, dated June 7, 2006, by and between Novogen Research Party Limited and Marshall Edwards Pty Limited.

99.1		Press Release issued by Marshall Edwards, Inc., dated as of June 7, 2006.

EX-10.1

Exhibit 10.1


	BLAKE DAWSON WALDRON

	L A W Y E R S

Amendment Deed

Novogen Research Pty Limited

ABN 87 060 202 931

Marshall Edwards Pty Limited

ABN 36 099 665 675

7 June 2006


Level 36
Grosvenor Place
225 George Street
Sydney NSW 2000
Telephone: +61 2 9258 6000		7 June 2006
Fax: +61 2 9258 6999		Ref: BLM 02 1372 3369

^©Blake Dawson Waldron 2006

CONTENTS


1.	INTERPRETATION		1
	1.1	Definitions	1
	1.2	Terms defined in the License Agreement	1
	1.3	Rules for interpreting this document	1
2.	CONSIDERATION		2
3.	AMENDMENT		2
	3.1	Amendments effective	2
	3.2	Amendments — Novogen Developments	2
	3.3	Amendments — Milestone License Fee	3
4.	REPRESENTATIONS AND WARRANTIES		4
	4.1	Representations and warranties	4
	4.2	Reliance on representations and warranties	5
5.	GENERAL		5
	5.1	Governing law	5
	5.2	Liability for expenses	2
	5.3	Giving effect to this document	5
	5.4	Amendment	5
	5.5	Counterparts	5

AMENDMENT DEED

DATE 7 June 2006

PARTIES


	Novogen Research Pty Limited ABN 87 060 202 931 of 140 Wicks Road, North Ryde NSW 2113 Australia (Novogen Research)

	Marshall Edwards Pty Limited ABN 36 099 665 675 of 140 Wicks Road, North Ryde NSW 2113 Australia (MEPL)

RECITALS

A. The parties are parties to the Licence Agreement.

B. The parties wish to amend the Licence Agreement on the terms of this document.

OPERATIVE PROVISIONS

1. INTERPRETATION

1.1 Definitions


	The following definitions apply in this document.

	Effective Date means the date this document is executed by the last of the parties to execute it.

	Licence Agreement means the agreement entitled “Amended and Restated Licence Agreement” between Novogen Research and MEPL dated 24 September 2003.

1.2 Terms defined in the Licence Agreement


	Terms that are not defined in clause 1.1 and that are defined in the Licence Agreement (as amended by this document) have the same meaning in this document.

1.3 Rules for interpreting this document


	Headings are for convenience only, and do not affect interpretation. The following rules also apply in interpreting this document, except where the content makes it clear that a rule is not intended to apply.


	(a)	A reference to:


	(i)	legislation (including subordinate legislation) is to that legislation as amended, re-enacted or replaced, and includes any subordinate legislation issued under it;


	(ii)	a document or agreement, or a provision of a document or agreement, is to that document, agreement or provision as amended, supplemented, replaced or novated;


	(iii)	a party to this document or to any other document or agreement includes a permitted substitute or a permitted assign of that party;


	(iv)	a person includes any type of entity or body of persons, whether or not it is incorporated or has a separate legal identity, and any executor, administrator or successor in law of the person; and


	(v)	anything (including a right, obligation or concept) includes each part of it.


	(b)	A singular word includes the plural, and vice versa.

	(c)	A word which suggests one gender includes the other genders.

	(d)	If a word is defined, another part of speech has a corresponding meaning.

	(e)	If an example is given of anything (including a right, obligation or concept), such as by saying it includes something else, the example does not limit the scope of that thing.


	(f)	The word agreement includes an undertaking or other binding arrangement or understanding, whether or not in writing.

2. CONSIDERATION

Each party acknowledges that it has received valuable consideration for entering into this document.

3. AMENDMENT

3.1 Amendments effective


	(a)	The Licence Agreement is amended with effect on the Effective Date in accordance with clauses 3.2 and 3.3.

	(b)	Subject to paragraph (c), paragraph (a) does not affect any right or obligation that arises before the Effective Date.

	(c)	The amendments in clause 3.2 are deemed to have taken effect on and from the date the Licence Agreement was executed by the last of the parties to execute it.

3.2 Amendments — Novogen Developments


	(a)	The definition of “Novogen Developments” is deleted and replaced with the following:


		“Novogen Developments” means all developments of, improvements to, enhancements to, or adaptations of Products or Licensed Know How, whether patentable or otherwise, in the Field which during the Term are made or acquired by Novogen Research, Novogen Limited or Novogen Laboratories Pty. Limited (ABN 42 002 489 947) or their employees, contractors or agents, which Novogen Research is free to license or disclose to MEPL, but does not include any Option


	Compound or any new isoflavonoid compound having a formula which does not fall within the claims of the Product Patent Rights.


	(b) After the definition of “Novogen Limited” the following definition is added:


	“Option Compound” has the meaning given in the document entitled “Amended and Restated Licence Option Deed” between Novogen Research and MEPL dated 24 September 2003.

3.3 Amendments — Milestone Licence Fee


	(a)	In the definition of “Milestone Licence Fee”, after paragraph (c), a new paragraph (d) is added as follows:


	(d)	upon the receipt by MEPL of the first:


	(i)	approval by the FDA of a New Drug Application (NDA) for a Product (on an accelerated basis or otherwise);


	(ii)	approval or authorisation of any kind to market a Product in the United States; or


	(iii)	approval or authorisation of any kind by a Government Agency in any other country to market a Product,


	(the Approval Date): US$8,000,000, together with interest on that amount from (and including) 31 December 2006 to (but excluding) the Approval Date, at the Bank Bill Rate;


	(b)	In the definition of “Milestone Licence Fee”, after new paragraph (d), existing paragraph (d) is renumbered (e) and the date “31 December 2005” is replaced with “31 December 2006”.

	(c)	After the definition of “Authorisation” the following definitions are added:


	“Bank Bill” means a bill of exchange (as defined in the Bills of Exchange Act 1909 (Cth)) that has been accepted by a bank authorised under a law of the Commonwealth or any state to carry on banking business.

	“Bank Bill Rate” means, for a period:


	(a)	the average, expressed as a yield per cent per annum (rounded up (if necessary) to 4 decimal places) of all rates quoted on each day in the period as the 180 day bank-accepted bill rate on the web site of the Reserve Bank of Australia at www.rba.gov.au (or any web site that replaces that web site); or

	(b)	if no rate can be calculated under paragraph (a), the bid rate available to MEPL at about 11:00 am (Sydney time) on that day, as conclusively determined in good faith by MEPL, for Bank Bills that have the tenor described in paragraph (a).

4. REPRESENTATIONS AND WARRANTIES

4.1 Representations and warranties

Each party represents and warrants that:


	(a)	(status) it is a company limited by shares under the Corporations Act;

	(b)	(power) it has full legal capacity and power:


	(i)	to own its property and assets and to carry on its business; and


	(ii)	to enter into this document and to carry out the transactions that it contemplates;


	(c)	(corporate authority) it has taken all corporate action that is necessary or desirable to authorise its entry into this document and its carrying out the transactions that it contemplates;

	(d)	(Authorisations) it holds each Authorisation that is necessary or desirable to:


	(i)	execute this document and to carry out the transactions that it contemplates; and


	(ii)	ensure that this document is legal, valid, binding and admissible in evidence,


	and it is complying with any conditions to which any of these Authorisations is subject;


	(e)	(document effective) this document constitutes its legal, valid and binding obligations, enforceable against it in accordance with its terms (except to the extent limited by equitable principles and laws affecting creditors’ rights generally), subject to any necessary stamping or registration;


	(f)	(no contravention) neither its execution of this document, nor the carrying out by it of the transactions that it contemplates, does or will:


	(i)	contravene any law to which it or any of its property is subject or any order of any Government Agency that is binding on it or any of its property;


	(ii)	contravene any Authorisation;


	(iii)	contravene any undertaking or instrument binding on it or any of its property; or


	(iv)	contravene its constitution; and


	(g)	(no trust) it is not entering into this document as trustee of any trust or settlement


4.2	Reliance on representations and warranties

Each party acknowledges that the other party has executed this document and agreed to take part in the transactions that it contemplates in reliance on the representations and warranties that are made or repeated in this clause.


5.	GENERAL


5.1	Governing law

This document is governed by the law in force in New South Wales.


5.2	Liability for expenses

Each party must pay its own expenses incurred in negotiating, executing, stamping and registering this document.


5.3	Giving effect to this document

Each party must do anything (including execute any document), and must ensure that its employees and agents do anything (including execute any document), that the other party may reasonably require to give full effect to this document.


5.4	Amendment

This document can only be amended, supplemented, replaced or novated by another document signed by the parties.


5.5	Counterparts

This document may be executed in counterparts.

EXECUTED as a deed.

EXECUTED by NOVOGEN
RESEARCH PTY LIMITED:




DAVID SEASON		RONALD LEA ERRATT

Name		Name

EXECUTED by MARSHALL
EDWARDS PTY LIMITED:




S. BRECKENRIDGE		DAVID SEASON

Name		Name

EX-99.1

Exhibit 99.1

ASX & MEDIA RELEASE
7 JUNE, 2006

NOVOGEN RENEGOTIATES PHENOXODIOL LICENCE PAYMENT

Novogen Limited (ASX: Novogen — Nasdaq: NVGN) has renegotiated with Marshall Edwards, Inc. (Nasdaq:

MSHL) the timing of an $US8 million milestone licence payment for phenoxodiol payable to Novogen Limited in December 2006, under the terms of the Licence Agreement for the anti-cancer drug phenoxodiol.

The terms of the Amendment Deed signed today, postpones the licence fee payment until phenoxodiol receives first approval for marketing the product in the USA or any other country. The marketing approval may be by the receipt of a New Drug Application under Accelerated Approval or otherwise.

MSHL’s President and CEO, Mr. Naughton, said the postponing of the licence fee payment would enable MSHL to focus its cash resources on completing the phase Ill clinical trial for which it had recently received approval of its Special Protocol Assessment from the US Food and Drug Administration (FDA).

“The milestone licence payment is now due when phenoxodiol is approved for market by the FDA.” Mr Naughton said.

Marshall Edwards, Inc. (Nasdaq : MSHL) is a US clinical oncology company and is majority owned by Novogen.

Novogen Limited (ASX: NRT — Nasdaq: NVGN), based in Sydney, Australia, is developing a range of therapeutics across the fields of oncology, cardiovascular, and inflammatory diseases.

More information on phenoxodiol and on the Novogen group of companies can be found at www.marshalledwardsinc.com and www.novogen.com.


ISSUED FOR:		NOVOGEN LIMITED
LISTINGS:		ASX (CODE NRT), NASDAQ (CODE NVGN).

FOR FURTHER INFORMATION:		CHRISTOPHER NAUGHTON, MANAGING DIRECTOR, NOVOGEN LIMITED
		TEL (02) 9878 0088 http://www.novogen.com

ISSUED BY		WESTBROOK COMMUNICATIONS
		CONTACT: DAVID REID TEL (02) 9231 0922 OR 0417 217 157

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents